-
Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes
Groen, K., Smits, F., Nasserinejad, K., Levin, M-D., Regelink, J. C., Timmers, G-J., de Waal, E. G. M., Westerman, M., Velders, G. A., de Heer, K., Leys, R. B. L., van Kampen, R. J. W., Stege, C. A. M., Seefat, M. R., Nijhof, I. S., van der Spek, E., Klein, S. K., van de Donk, N. W. C. J., Ypma, P. F. & Zweegman, S., 1 Jul 2024, In: HemaSphere. 8, 7, e85.Research output: Contribution to journal › Comment/Letter to the editor › Academic
-
Prophylactic tocilizumab reduces the incidence of cytokine release syndrome in relapsed/refractory myeloma patients treated with teclistamab: Implications for outpatient step-up dosing
Korst, C. L. B. M., Groen, K., Bosman, P. W. C., van der Valk, F., Verkleij, C. P. M., Kruyswijk, S., de Ruijter, M. E. M., Heijink, D. M., Kuipers, M. T., Zweegman, S. & van de Donk, N. W. C. J., 1 Jul 2024, In: HemaSphere. 8, 7, e132.Research output: Contribution to journal › Letter › Academic › peer-review
-
Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation
Frerichs, K. A., Verkleij, C. P. M., Mateos, M. V., Martin, T. G., Rodriguez, C., Nooka, A., Banerjee, A., Chastain, K., Perales-Puchalt, A., Stephenson, T., Uhlar, C., Kobos, R., van der Holt, B., Kruyswijk, S., Kuipers, M. T., Groen, K., Vishwamitra, D., Skerget, S., Cortes-Selva, D., Doyle, M., & 4 others, 9 Jan 2024, In: Blood. 8, 1, p. 194-206 13 p.Research output: Contribution to journal › Article › Academic › peer-review
- All publications
